Standard
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. / Olotu, Ally; Lusingu, John; Leach, Amanda; Lievens, Marc; Vekemans, Johan; Msham, Salum; Lang, Trudie; Gould, Jayne; Dubois, Marie-Claude; Jongert, Erik; Vansadia, Preeti; Carter, Terrell; Njuguna, Patricia; Awuondo, Ken O; Malabeja, Anangisye; Abdul, Omar; Gesase, Samwel; Mturi, Neema; Drakeley, Chris J; Savarese, Barbara; Villafana, Tonya; Lapierre, Didier; Ballou, W Ripley; Cohen, Joe; Lemnge, Martha M; Peshu, Norbert; Marsh, Kevin; Riley, Eleanor M; von Seidlein, Lorenz; Bejon, Philip.
In:
Lancet Infectious Diseases, Vol. 11, No. 2, 2011, p. 102-9.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Olotu, A, Lusingu, J, Leach, A, Lievens, M, Vekemans, J, Msham, S, Lang, T, Gould, J, Dubois, M-C, Jongert, E, Vansadia, P, Carter, T, Njuguna, P, Awuondo, KO, Malabeja, A, Abdul, O, Gesase, S, Mturi, N, Drakeley, CJ, Savarese, B, Villafana, T, Lapierre, D, Ballou, WR, Cohen, J, Lemnge, MM, Peshu, N, Marsh, K, Riley, EM, von Seidlein, L & Bejon, P 2011, '
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial',
Lancet Infectious Diseases, vol. 11, no. 2, pp. 102-9.
https://doi.org/10.1016/S1473-3099(10)70262-0APA
Olotu, A., Lusingu, J., Leach, A., Lievens, M., Vekemans, J., Msham, S., Lang, T., Gould, J., Dubois, M-C., Jongert, E., Vansadia, P., Carter, T., Njuguna, P., Awuondo, K. O., Malabeja, A., Abdul, O., Gesase, S., Mturi, N., Drakeley, C. J., ... Bejon, P. (2011).
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial.
Lancet Infectious Diseases,
11(2), 102-9.
https://doi.org/10.1016/S1473-3099(10)70262-0Vancouver
Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S et al.
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial.
Lancet Infectious Diseases. 2011;11(2):102-9.
https://doi.org/10.1016/S1473-3099(10)70262-0Author
Olotu, Ally ; Lusingu, John ; Leach, Amanda ; Lievens, Marc ; Vekemans, Johan ; Msham, Salum ; Lang, Trudie ; Gould, Jayne ; Dubois, Marie-Claude ; Jongert, Erik ; Vansadia, Preeti ; Carter, Terrell ; Njuguna, Patricia ; Awuondo, Ken O ; Malabeja, Anangisye ; Abdul, Omar ; Gesase, Samwel ; Mturi, Neema ; Drakeley, Chris J ; Savarese, Barbara ; Villafana, Tonya ; Lapierre, Didier ; Ballou, W Ripley ; Cohen, Joe ; Lemnge, Martha M ; Peshu, Norbert ; Marsh, Kevin ; Riley, Eleanor M ; von Seidlein, Lorenz ; Bejon, Philip. / Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. In: Lancet Infectious Diseases. 2011 ; Vol. 11, No. 2. pp. 102-9.
Bibtex
@article{bb280ac8b86644a7b2dcebd883e94a9d,
title = "Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial",
abstract = "RTS,S/AS01E is the lead candidate malaria vaccine. We recently showed efficacy against clinical falciparum malaria in 5-17 month old children, during an average of 8 months follow-up. We aimed to assess the efficacy of RTS,S/AS01E during 15 months of follow-up.",
author = "Ally Olotu and John Lusingu and Amanda Leach and Marc Lievens and Johan Vekemans and Salum Msham and Trudie Lang and Jayne Gould and Marie-Claude Dubois and Erik Jongert and Preeti Vansadia and Terrell Carter and Patricia Njuguna and Awuondo, {Ken O} and Anangisye Malabeja and Omar Abdul and Samwel Gesase and Neema Mturi and Drakeley, {Chris J} and Barbara Savarese and Tonya Villafana and Didier Lapierre and Ballou, {W Ripley} and Joe Cohen and Lemnge, {Martha M} and Norbert Peshu and Kevin Marsh and Riley, {Eleanor M} and {von Seidlein}, Lorenz and Philip Bejon",
note = "Copyright {\textcopyright} 2011 Elsevier Ltd. All rights reserved.",
year = "2011",
doi = "10.1016/S1473-3099(10)70262-0",
language = "English",
volume = "11",
pages = "102--9",
journal = "The Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "TheLancet Publishing Group",
number = "2",
}
RIS
TY - JOUR
T1 - Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial
AU - Olotu, Ally
AU - Lusingu, John
AU - Leach, Amanda
AU - Lievens, Marc
AU - Vekemans, Johan
AU - Msham, Salum
AU - Lang, Trudie
AU - Gould, Jayne
AU - Dubois, Marie-Claude
AU - Jongert, Erik
AU - Vansadia, Preeti
AU - Carter, Terrell
AU - Njuguna, Patricia
AU - Awuondo, Ken O
AU - Malabeja, Anangisye
AU - Abdul, Omar
AU - Gesase, Samwel
AU - Mturi, Neema
AU - Drakeley, Chris J
AU - Savarese, Barbara
AU - Villafana, Tonya
AU - Lapierre, Didier
AU - Ballou, W Ripley
AU - Cohen, Joe
AU - Lemnge, Martha M
AU - Peshu, Norbert
AU - Marsh, Kevin
AU - Riley, Eleanor M
AU - von Seidlein, Lorenz
AU - Bejon, Philip
N1 - Copyright © 2011 Elsevier Ltd. All rights reserved.
PY - 2011
Y1 - 2011
N2 - RTS,S/AS01E is the lead candidate malaria vaccine. We recently showed efficacy against clinical falciparum malaria in 5-17 month old children, during an average of 8 months follow-up. We aimed to assess the efficacy of RTS,S/AS01E during 15 months of follow-up.
AB - RTS,S/AS01E is the lead candidate malaria vaccine. We recently showed efficacy against clinical falciparum malaria in 5-17 month old children, during an average of 8 months follow-up. We aimed to assess the efficacy of RTS,S/AS01E during 15 months of follow-up.
U2 - 10.1016/S1473-3099(10)70262-0
DO - 10.1016/S1473-3099(10)70262-0
M3 - Journal article
C2 - 21237715
VL - 11
SP - 102
EP - 109
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
SN - 1473-3099
IS - 2
ER -
